Monitor Q4 2026 earnings call for formal 2027 guidance. The LRP targets are aspirational and depend on market normalization; watch for execution on Signals Software SaaS penetration growth and Immunodiagnostics geographic expansion as leading indicators.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $154.39entry
- T+1 · 17h ago −3.59%α −1.68% · $148.85
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Revvity held its 2026 Investor Day, presenting its long-range financial outlook with 6-8% organic revenue growth (200bps above market), double-digit adjusted EPS growth, and 75bps annual operating margin expansion. The company provided segment-level LRP organic growth targets: Life Sciences Solutions 6-8%, Immunodiagnostics 7-9%, Reproductive Health 3-5%, and Signals Software 10-12% APV. 2027 considerations include ~6% organic growth, ~$85M net interest, ~19% tax rate, and flat share count.
Key Facts
- 2026E revenue ~$2.9B, with ~55% Life Sciences and ~45% Diagnostics
- LRP organic growth targets: Life Sciences Solutions 6-8%, Immunodiagnostics 7-9%, Reproductive Health 3-5%, Signals Software 10-12% APV
- Long-term financial outlook: 6-8% organic revenue growth (200bps above market), double-digit adjusted EPS growth, 75bps annual operating margin expansion
- 2027 considerations: ~6% organic growth, ~200bps above market, ~20bps additional operating leverage, net interest ~$85M, tax rate ~19%, flat share count
- Signals Software metrics: 2026E ARR >$275M (13% CAGR from 2020), APV >$130M (47% CAGR), SaaS penetration ~35% (40% CAGR), net retention rate ~107% historical average
- Adj. operating margin ~28.8% for 2026E, with target of mid-30s% over time
- Since 2022: adj. EPS grew from ~$2B to ~$5.43 (2026E), free cash flow >$575M with >90% FCF conversion, 12% reduction in share count
- ~$5B of capital capacity through 2031 with commitment to investment-grade credit rating
- Diagnostics segment LRP organic growth: 5-7% (Immunodiagnostics 7-9%, Reproductive Health 3-5%)
- Life Sciences segment LRP organic growth: 7-9% (Life Sciences Solutions 6-8%, Signals Software 10-12% APV)
Financial Impact
Long-range plan targets 6-8% organic revenue growth with double-digit adjusted EPS growth and 75bps annual margin expansion; 2027 guided ~6% organic growth
Risk Factors
- Forward-looking statements are aspirational and subject to market conditions, pharma/biotech spending, and geopolitical uncertainty
- Life Sciences Solutions segment has been flat (CAGR since becoming Revvity) and needs market normalization to achieve 6-8% LRP growth
- Reproductive Health faces birth rate headwind of -200bps, partially offset by menu expansion and geographic growth
- Immunodiagnostics China business under definitive agreement to be divested, creating uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-073578 |
| Document: pki-20261113.htm | 0001628280-26-073578 |
| Document: a2026investordaypressrelea.htm | 0001628280-26-073578 |
| Document: 0001628280-26-073578-index-headers.html | 0001628280-26-073578 |
| Document: 0001628280-26-073578-index.html | 0001628280-26-073578 |
| Document: 0001628280-26-073578.txt | 0001628280-26-073578 |
Track record
9 reports on RVTY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.31% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.85 −1.28% settles Dec 15
- Nov 13, 20263d ago 8-K Neutral 4/10 Viewing Entry $154.39 Now $148.85 −3.59% settles Dec 14
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $163.48 Now $148.85 −8.95% settles Dec 2
- Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.85 −3.74% ▲ +2.33% +3.75% vs SPY
- Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.85 −3.09% ▲ +3.80% +5.13% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.85 +1.17% ▼ −4.43% −4.85% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 Entry $111.39 to $126.59 Now $148.85 +33.63% ▲ +13.65% +14.88% vs SPY
- May 5, 202627w ago 8-K Mixed 5/10 Entry $92.30 to $100.39 Now $148.85 +61.27% ▲ +8.76% +3.81% vs SPY
- Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.85 +72.26% ▲ +8.13% +4.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers